Department of General Surgery, Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey.
Department of Pathology, Nevşehir State Hospital, Nevşehir, Turkey.
Turk J Med Sci. 2021 Dec 13;51(6):2994-3000. doi: 10.3906/sag-2103-148.
BACKGROUND/AIM: Paget’s disease (PD) of the breast is a very rare presentation of breast malignancy, accounting for 1%–3% of all primary breast tumors. We aimed to evaluate and compare the clinicopathological features and clinical outcome of PD accompanied by in situ carcinoma and invasive cancer.
We used the archive of our pathology laboratory retrospectively for age, sex, history of surgery, histopathological findings, treatment modalities, and follow-up information. We used the Kaplan–Meier method for survival analysis.
There were 46 female patients diagnosed with PD. In 39 (84.7%) patients, invasive carcinoma accompanied PD, while 7 (15.3%) patients had ductal carcinoma in situ. The median age at diagnosis was 53.5 years. The median follow-up period was 47 months. Of the 39 invasive carcinoma, 10 (25.6%) died during the follow-up period. Invasive ductal carcinoma group had a mean overall survival of rate of 57.8 ± 6.6 months. According to univariate analysis, only the tumor type was found to impact overall survival (p < 0.001).
The current study displayed the tumor type as the only parameter affecting overall survival in the invasive carcinoma group. Although it was not statistically significant, breast cancers accompanied by PD were found to be predominantly advanced stage tumors, high grade, hormone receptor negative, and HER2 positive.
背景/目的：乳腺佩吉特病（PD）是一种非常罕见的乳腺恶性肿瘤表现，占所有原发性乳腺肿瘤的 1%-3%。我们旨在评估和比较伴有原位癌和浸润性癌的 PD 的临床病理特征和临床结果。
我们使用我们病理实验室的档案，回顾性地获取年龄、性别、手术史、组织病理学发现、治疗方式和随访信息。我们使用 Kaplan-Meier 方法进行生存分析。
共有 46 名女性患者被诊断为 PD。在 39 名（84.7%）患者中，浸润性癌伴有 PD，而 7 名（15.3%）患者患有导管原位癌。诊断时的中位年龄为 53.5 岁。中位随访时间为 47 个月。在 39 例浸润性癌中，有 10 例（25.6%）在随访期间死亡。浸润性导管癌组的总生存率为 57.8±6.6 个月。通过单因素分析，只有肿瘤类型被发现对总生存率有影响（p<0.001）。
本研究显示，肿瘤类型是浸润性癌组中唯一影响总生存率的参数。虽然没有统计学意义，但伴有 PD 的乳腺癌被发现主要是晚期肿瘤、高级别、激素受体阴性和 HER2 阳性。
